Friday, July 10, 2026

pharma · Diphtheria · Diabetes Mellitus, Type 2

Sanofi Pasteur MSD

Sanofi Pasteur MSD clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

France, LYON HQ
363 Employees
EMA registrant Type
Company details
Status
Public
HQ
France, LYON
Employees
363
Programs
83
Drugs
66
Patents
0
Intelligence · Clinical Programs

Sanofi Pasteur MSD projects

3 ClinicalTrials.gov programs sponsored by Sanofi Pasteur MSD.

Sanofi Pasteur MSD has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. SAR448501

    Sanofi Pasteur

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial
  2. ombrabulin (AVE8062)

    Sanofi Pasteur

    Neoplasms, Malignant

    phase 1 small molecule completed

    1 trial
  3. sarilumab SAR153191 (REGN88)

    Sanofi Pasteur

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Sanofi Pasteur MSD have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.